U.S. stocks fell and precious metals plunged from record highs after President Trump nominated former Fed Governor Kevin Warsh to lead the central bank, sparking concerns over monetary policy direction and Fed independence.
Gold and silver futures plummeted Friday, erasing recent gains in a dramatic reversal. The sharp decline coincided with broader market jitters and followed warnings that the metals' explosive rally had entered unsustainable territory.
Alibaba-backed Moonshot AI has unveiled an upgraded flagship model, Kimi K2.5, asserting superiority in video generation and agentic capabilities against leading U.S. models. The development coincides with Beijing's approval for major tech firms, including Alibaba, to import advanced Nvidia H200 AI chips, signaling a dual-track strategy in the intensifying global AI race.
A stunning reversal wiped out months of gains for precious metals on Friday, with gold futures tumbling to $4,800 and silver recording a historic single-day drop, sparking fears of a volatile new phase for commodity markets.
The White House has backed away from plans to set minimum prices for domestic critical minerals projects, telling industry leaders that ventures must stand on their own financially. The policy reversal, driven by funding uncertainties and market concerns, marks a significant shift in strategy for bolstering the U.S. supply chain.
Amneal Pharmaceuticals' shares have surged over 64% in the past year, prompting investors to question if the rally still has room to run. A closer look at valuation metrics suggests the generic drugmaker may still be trading at a significant discount to its intrinsic value.
Recent drill results from Sun Silver's Maverick Springs project in Nevada have delivered high-grade silver and gold intercepts, alongside a meaningful discovery of antimony mineralization. This development strengthens the geological model for the large inferred resource and introduces a critical-minerals dimension, potentially reshaping the project's value proposition for shareholders.
As XRP enters a historically weak month, conflicting signals from whale accumulation, ETF flows, and exchange deposits set the stage for a volatile February 2026. Analysts pinpoint key levels that will determine the token's near-term trajectory.
A human rights group has cautioned New York state and city officials that investing public funds in Israeli government bonds may violate international law and fiduciary duties, exposing them to significant legal and financial risks.
Silvercorp Metals has solidified its expansion into Central Asia by acquiring a majority stake in Chaarat ZAAV CJSC, forming a joint venture with state-owned Kyrgyzaltyn to develop permitted gold projects. The move signals a strategic pivot for the historically silver-focused miner as it seeks to balance geographic and commodity risks.
The Rafah border crossing between Gaza and Egypt is set to partially reopen Sunday, marking a fragile step in the U.S.-brokered ceasefire. While offering a lifeline for medical evacuees and displaced families, the operation will be tightly controlled by Israeli, Egyptian, and EU officials, with significant restrictions on the movement of people and goods.
Minerals 260 (ASX:MI6) has significantly upgraded the resource estimate at its flagship Bullabulling gold project to 4.5 million ounces, sparking renewed investor interest. Despite recent share price volatility, the long-term outlook appears buoyed by upcoming study milestones and a substantial intrinsic value gap, raising questions about whether the market is undervaluing its potential.
Denmark's government announced a bold legislative package aimed at expanding deportations and tightening immigration controls, setting the stage for a potential clash with the European Court of Human Rights.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
Semiconductor security firm SEALSQ deepens its investment in France, now employing around 200 specialists across its Toulouse, Aix-en-Provence, and Grenoble offices, positioning the country as a core R&D center for its post-quantum cryptography and secure chip technologies.
Eli Lilly bolsters its long-term growth strategy through two new R&D partnerships and a key regulatory milestone for an ovarian cancer drug, signaling a strategic push beyond its blockbuster diabetes and obesity treatments.
TD Cowen lowered its price target on Atlassian (TEAM) ahead of earnings, highlighting strong fundamentals in service management and cloud migration but flagging weak traction in AI as a key medium-term overhang for the stock.
Analysts at Bernstein reaffirm an Outperform rating for Datadog, noting the company's strategic focus appears to be on internal development and smaller tech tuck-ins rather than pursuing large-scale deals like a potential GitLab acquisition.
Wells Fargo has upgraded Broadcom (AVGO) to Overweight and increased its price target to $430, pointing to the chipmaker's significant AI revenue trajectory and a robust software pipeline as key growth drivers through 2027.
